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Abstract
Background
Pain is a common symptom related to inflammatory bowel disease (IBD). In addition to
abdominal pain, pain can also be an extraintestinal manifestation of IBD. Pain treatment is
challenging and a substantial part of IBD patients are treated with opioids. Therefore, a bet-
ter knowledge on pain symptoms is crucial for a better therapeutic approach to this clinical
problem.
Methods
Patients of the Swiss IBD Cohort Study (SIBDCS) (n = 2152) received a questionnaire
regarding pain intensity, pain localization and impact of pain on daily life and social activi-
ties. Furthermore, the questionnaire investigated the use of pain-specific medication.
Results
A vast majority of patients (71%) experienced pain during the disease course. For a sub-
stantial part of patients (49% in UC and 55% in CD) pain is a longstanding problem (>5
years). Pain in UC was of shorter duration compared to CD (p < 0.01). Abdominal pain
(59.5%) and back pain (38.3%) were the main pain localizations. 67% of patients took pain
medication; 24% received no pain treatment. The general quality of life was significantly
lower in patients suffering of pain compared to those without pain (38 vs. 77; (-100 very bad;
100 very good) p<0.0001).
Conclusions
Prevalence of pain is high in patients of the SIBDCS. It is a longstanding problem for the
majority of the patients affected. Pain was found to be undertreated in the SIBDCS and was
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significantly associated with health-related quality of life. Thus, an increased awareness is
mandatory to address this frequent complication in the course of IBD.
Introduction
Abdominal pain is a common symptom related to Crohn’s disease (CD) and ulcerative colitis
(UC), also collectively known as inflammatory bowel disease (IBD). During disease flares pain
is present in 50–70% of IBD patients[1, 2]. Pain can also be caused by extraintestinal manifesta-
tions (EIM) of IBD or can be an extraintestinal manifestation by itself and more than 40% of
IBD patients suffer from EIM[3–5] With a prevalence in the literature of 1–46%, arthropathies
are the most common EIM of IBD[4, 6–16].
Pronounced severe impact of pain on health related quality of life (HRQOL) is known for
various diseases[17–20]. Longstanding pain leads to a significant decrease in HRQOL, increase
in pain medication intake and comorbidities including depression, anxiety and addiction [21–
23]. Lower HRQOL also has been shown to result in an increased healthcare utilization among
youth with IBD[24]. Furthermore, pain attacks severely interfere with social and working hab-
its [25–27]. In an analysis of the data from the SIBDCS it could be shown that EIM were one of
the most important predictors for temporary work disability in patients with CD[28].
In a German study including some 300 patients using a specifically designed questionnaire
regarding pain and HRQOL 87.9% of IBD patients reported pain and showed a significantly
reduced HRQOL. Surgery reduced pain and patients on analgesics reported more pain and
lower HRQOL than patients not on analgesics [29].
Pain may directly be caused by inflammation as inflammatory cytokines and mediators
have been shown to sensitize primary afferent neurons[30]. But ongoing inflammation does
not fully explain pain in many IBD patients: about 20% of patients in complete clinical and
endoscopic remission continue to experience pain. Pain treatment is complex and challenging.
Pain perception in IBD patients may be influenced by multiple factors; peripheral, central, and
environmental (stress) factors [31]. Pain treatment is challenging. NSAIDs can be very effective
medications for arthralgia, arthritis or other rheumatic diseases, but their use in IBD is limited
due to the risk of disease exacerbation and disease flares[32–38]. Even up to one-sixth of IBD
patients in USA are chronically treated with opioids[39, 40]. Furthermore, pain in IBD was
identified as the most common cause (48% of cases) for readmission 4 weeks after discharge
from the hospital[41].
Here, we evaluated the well-characterized patient collective of the SIBDCS regarding pain,
its impact of pain on daily life and social activities and the use of pain-specific medication.
With 1’263 IBD patients included we present, to our best knowledge, the most extensive analy-
sis of pain in IBD up to date.
Methods
Study Design
In the nationwide Swiss IBD Cohort Study (SIBDCS) patients with IBD from all regions of
Switzerland have prospectively been included since 2006. In the SIBDCS at inclusion retrospec-
tive data is collected and afterwards patients are followed-up on a yearly basis. The cohort
study is supported by the Swiss National Science Foundation and approved by the local ethical
committees (IRB approval number: EK-1316, approved on 05.02.2007 by the Cantonal Ethics
Committee of the Canton Zürich, Switzerland). As a participant of the SIBDCS the patients
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gave written informed consent for their clinical records to be used in this study. The cohort
goals and methodology are described elsewhere[42].
2152 adult patients of the SIBDCS received a questionnaire regarding pain localization,
impact of pain on daily life, how the surrounding responds to the patients’ pain and how activi-
ties of daily life are influenced. Furthermore, the questionnaire investigated the use of pain-
specific medication. To develop the questionnaire, we used the validated German pain ques-
tionnaire[43]. Out of the 25 items in the German pain questionnaire 16 items were taken into
our questionnaire (we used items 5, 6, 7, 8, 9, 10, 11, 12, 14, 15, 16, 18, 20, 21, 22, A1). Within
these questions the patients were asked to mark their pain localizations in a body scheme and
define the duration of the occurrence of pain (differentiating less than a month, 1 month–½
year, ½ year– 1 year, 1–2 years, 2–5 years and>5 years). Furthermore, they had to define the
pain attacks regarding duration, frequency, intensity and quality and the patients were ques-
tioned about medical and non-medical treatment of pain and the impact of pain on their duties
of daily life and work. We used a German and a French version of the questionnaire. The ques-
tionnaires are included in the supporting information (S1 and S2 Files).
Statistical Analysis
Clinical data were retrieved from the data center of the SIBDCS at the University of Lausanne.
These data and additional data obtained from a review of the patients' files were entered into a
database (Access 2000; Microsoft Switzerland Ltd Liab. Co., Wallisellen, Switzerland).
A descriptive statistical analysis was performed. Categorical variables were summarized as
frequencies and percentages, whereas quantitative variables as median and range. Differences
in categorical data distribution between groups were assessed using the Chi-squared test, or the
Fisher’s exact test in case of insufficient sample size. The general wellbeing was analyzed by stu-
dent’s t-test. For the analysis of the disease duration the Wilcoxon-Mann-Whitney ranksum
test was used. A p-value< 0.05 was considered statistically significant. All statistical analyses
were carried out using GraphPad Prism 5.04 for Windows (GraphPad Software Inc.).
Results
Patient’s characteristics
We received 1263 completed questionnaires (response rate 59%). 599 from 1263 of the patients
were male (47%) and 664 were female (53%). The median age was 47 years. 679 patients had
the diagnosis of CD (54%), 556 UC (44%), 28 indeterminate colitis (IC) (2%). EIM of IBD
were present in 699 patients (55%). The median disease duration was 15 years (0–57 years)
(Table 1). The mean disease duration of all IBD patients was 15 years (0–57 years). In a sub-
group analysis the mean disease duration of CD patients was longer (16 years (0–57 years))
than in UC (14 years (0–49) which was statistically significant (p = 0.002). The last disease
location can be seen in Table 1.
Prevalence of pain in IBD
A total of 1263 completed questionnaires was analyzed regarding pain. The vast majority of
patients (894, 71%) reported having experienced pain in general during the course of the
disease. Only 369 (29%) of the patients that sent back the questionnaire reported no pain
(Table 1). There was no statistical difference when comparing CD and UC regarding the occur-
rence of pain (P = 0.5726) (Table 1). When comparing the prevalence of pain in patients with
any extraintestinal manifestation (EIM) and without, slightly more patients with EIM (73%;
Pain in IBD
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508 of 699 patients with EIM versus 68%; 386 of 564 patients without EIM) reported pain, but
this did not reach statistical significance (p = 0.1058).
Duration and evolution of pain in IBD
Pain was a longstanding problem for the majority of the patients with 52% (469 patients) of
patients experiencing pain>5 years. Fifteen patients (2%) reported pain since<1 month, 57
patients (6%) suffered from pain since 1 month—½ year, 59 patients (7%) since ½ year– 1
year, 79 patients (9%) since 1–2 years and 215 (24%) since 2–5 years (Table 2). When compar-
ing CD and UC 388 (70%) of the 556 UC patients reported pain in general. Of these the major-
ity (191 patients, 49%) reported to suffer from pain more than 5 years. The 679 CD patients on
the other hand also reported about pain in 71% (484 patients); of these a majority (265 patients,
55%) also suffered from pain>5 years. When comparing the duration of pain statistically
more UC patients (47 patients; 12%) only suffered from pain in the last 1–2 years compared to
CD (30 patients, 6%; p = 0.0026). For the other durations of pain there was no statistical differ-
ence (Table 2).
Table 1. Patient characteristics.
Total IBD Crohn’s Disease Ulcerative colitis
N(%) N(%) N(%) p-value
Gender
Female 664 (53) 375 (55) 275 (49)
Male 599 (47) 304 (45) 281 (51)
Diagnosis 1263 (100) 679 (54) 556 (44)
Pain
Yes 894 (71) 484 (71) 388 (70) p = 0.5726
No 369 (29) 195 (29) 168 (30)
EIM
Yes 699 (55) 421 (62) 266 (48)
No 564 (45) 258 (38) 290 (52)
Disease duration Years
Average 15
Min-max 0–57
Last disease location
Crohn’s disease (Montreal
classiﬁcation)
L1 only 186 (27)
L1+L4 9 (1)
L2 only 230 (34)
L2+L4 9 (1)
L3 only 198 (29)
L3+L4 12 (2)
L4 only 16 (2)
Unknown/unclear 19 (3)
Ulcerative colitis
Left-sided colitis 231 (42)
Pancolitis 189 (34)
Proctitis 127 (23)
Unknown/unclear 9 (2)
doi:10.1371/journal.pone.0156666.t001
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When characterizing the pain of all 894 IBD patients reporting of pain in general, 493
patients (55%) had pain attacks with no pain in between and 111 patients (12%) had pain
attacks without being completely free of pain in between. 162 patients (18%) had a constant
pain with slight fluctuations, 80 patients (9%) had constant pain with strong fluctuation. 48
patients (5%) did not specify (Table 3). When analysing the 484 CD patients who reported
pain 268 patients (55%) reported about pain attacks with no pain in between, 67 (14%) had
pain attacks without being completely free of pain in between. 91 (19%) had a constant pain
with slight fluctuation, while 44 (9%) had a constant pain with strong fluctuation. When ana-
lysing the 556 UC patients 209 patients (54%) reported about pain attacks with no pain in
between, 41 (11%) had pain attacks without being completely free of pain in between. 69 (18%)
had a constant pain with slight fluctuation, while 34 (9%) had a constant pain with strong fluc-
tuation. There was no statistically difference in the evolution of pain between CD und UC
(Table 3).
Frequency of pain in IBD
When characterizing the pain attacks of the 894 patients reporting pain in general, 173 patients
(19%) had pain multiple times a day, 50 (6%) once daily, 137 (15%) multiple times per week,
38 (4%) once per week, 138 (15%) multiple times per month with only 73 patients (8%) report-
ing of pain once a month and 155 patients (17%) less than monthly. 130 patients (15%) did not
specify (Table 4).
When comparing CD and UC patients in the group of CD patients presenting with pain
104 patients (21%) had pain multiple times a day, 26 (5%) once daily, 86 (18%) multiple times
per week, 19 (4%) once per week, 66 (14%) multiple times per month, 36 (7%) once per month
Table 2. Period suffering from pain.
Total IBD Crohn’s Disease Ulcerative colitis
Pain peroid N(%) N(%) N(%) p-value
<1 month 15 (2) 6 (1) 9 (3) p = 0.2956
1 month—½ year 57 (6) 34 (7) 20 (5) p = 0.4006
½ year-1 year 59 (7) 30 (6) 27 (7) p = 0.6807
1–2 years 79 (9) 30 (6) 47 (12) p = 0.0026
2–5 years 215 (24) 119 (25) 93 (24) p = 0.8739
>5 years 469 (52) 265 (55) 191 (49) p = 0.1166
No pain 369 (29.2)
doi:10.1371/journal.pone.0156666.t002
Table 3. Pain characterization.
Total IBD Crohn’s Disease Ulcerative colitis
Pain character N(%) N(%) N(%) p-value
Constant pain w. slight
ﬂuctuation
162 (18) 91 (19) 69 (18) p = 0.7253
Constant pain w. strong
ﬂuctuation
80 (9) 44 (9) 34 (9) p = 0.9054
Pain attacks w. pain free
intervals
493 (55) 268 (55) 209 (54) p = 0.6815
Pain attacks w. constant
pain
111 (12) 67 (14) 41 (11) p = 0.1492
Not speciﬁed 48 (5) 14 (3) 34 (9) p = 0.0002
doi:10.1371/journal.pone.0156666.t003
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and 82 (17%) less than monthly. 65 (13%) did not specify. In the analysis of the UC patients 66
patients (17%) had pain multiple times a day, 21 (5%) once daily, 49 (13%) multiple times per
week, 19 (5%) once per week, 64 (16%) multiple times per month, 36 (9%) once per month
and 69 (18%) less than monthly. 64 patients (16%) did not specify. More CD patients (86
patients, 18%) reported of pain multiple times per week compared with UC (49 patients, 13%;
p = 0.0385 (Table 4).
Duration and intensity of pain episodes in IBD
The pain attacks most often had a duration of minutes (229 patients, 26%) to hours (244
patients, 27%), in 11% (102 patients) the pain duration was seconds and in 10% (93 patients)
up to 3 days with only 73 patients (8%) reporting pain over more than 5 days. 153 patients
(17%) did not specify the pain attacks (Table 5). In the subgroup analysis in the group of CD
patients similar results were found with a pain duration of minutes (130 patients, 27%) to
hours (124 patients, 26%), in 13% (63 patients) the pain duration was seconds and in 11% (55
patients) up to 3 days with 8% (38 patients) reporting pain over more than 5 days. 74 patients
(15%) did not specify. In the group of UC patients there was a pain duration of minutes (92
patients, 24%) to hours (114 patients, 29%), in 10% (37 patients) the pain duration was seconds
and in 9% (35 patients) up to 3 days with 8% (32 patients) reporting pain over more than 5
days. 78 patients (20%) did not specify. There was no statistically difference between CD und
UC (Table 5).
The median pain intensity in the past 4 weeks was 2/10. 235 patients (26%) had no pain in
the previous 4 weeks. The greatest pain intensity in the last 4 weeks was a median of 3/10.
Table 4. Frequency of pain attacks.
Total IBD Crohn’s Disease Ulcerative colitis
Frequency of pain attacks N(%) N(%) N(%) p-value
Multiple daily 173 (19) 104 (21) 66 (17) p = 0.1027
1x/day 50 (6) 26 (5) 21 (5) p = 1.000
Multiple/week 137 (15) 86 (18) 49 (13) p = 0.0385
1x/week 38 (4) 19 (4) 19 (5) p = 0.5080
Multiple/month 138 (15) 66 (14) 64 (16) p = 0.2518
1x/month 73 (8) 36 (7) 36 (9) p = 0.3863
More seldom 155 (17) 82 (17) 69 (18) p = 0.7872
Not speciﬁed 130 (15) 65 (13) 64 (16) p = 0.2133
doi:10.1371/journal.pone.0156666.t004
Table 5. Duration of pain attacks.
Total IBD Crohn’s Disease Ulcerative colitis
Duration of pain attacks N(%) N(%) N(%) p-value
Seconds 102 (11) 63 (13) 37 (10) p = 0.1341
Minutes 229 (26) 130 (27) 92 (24) p = 0.3096
Hours 244 (27) 124 (26) 114 (29) p = 0.2211
< 3 days 93 (10) 55 (11) 35 (9) p = 0.2654
3 days 73 (8) 38 (8) 32 (8) p = 0.9003
Not speciﬁed 153 (17) 74 (15) 78 (20) p = 0.0723
Seconds 102 (11) 63 (13) 37 (10) p = 0.1341
Minutes 229 (26) 130 (27) 92 (24) p = 0.3096
doi:10.1371/journal.pone.0156666.t005
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Pain localization
Most of the 894 patients who reported pain suffered from abdominal pain (532 patients,
59.5%), followed by back pain in 342 patients (38.3%), knee pain in 258 patients (28.9%) and
hip pain in 231 patients (25.8%). 220 patients (24.6%) reported headaches, 132 patients neck
pain (14.8%), 204 patients (22.8%) pain in the hand and finger joints, 90 patients (10.1%)
reported pain in the elbows, 192 patients (21.5%) shoulder pain and 16.6% (148 patients)
reported pain in the feet/ankles. 312 patients (34.9%) did not specify (Table 6).
In the subgroup analysis there was no relevant difference in the pain localization in the CD
and UC patients (Table 6).
Treatment of pain
The majority of the 894 patients reporting of pain (600 patients, 67%), received pain medication.
Only 116 patients (13%) had physiotherapy. 216 patients (24%) received no pain treatment.
When accessing the kind of medical pain treatment, the majority of 37% (333 patients) used
Acetaminophen. Only 112 patients (13%) used NSAID and COX-2 inhibitors were used sel-
dom (3%, 22 patients). Opioids or Metamizole were used in 16% (142 patients) while 239
patients (27%) did not specify (Table 7). In a subgroup analysis of the CD and UC patients
reporting pain slightly more CD patients used Acetaminophen (39%, 189 patients) compared
to UC (34%, 131 patients), but this was not statistically significant (p = 0.2918). For NSAIDs,
COX-2 inhibitors, opioids and Metamizole there was no statistical difference when comparing
CD and UC (Table 7).
Table 6. Pain localization.
Total IBD Crohn’s Disease Ulcerative colitis
Pain localization N(%) N(%) N(%) p-value
Head 220 (24.6) 123 (25) 92 (24) p = 0.5807
Neck 132 (14.8) 75 (16) 56 (14) p = 0.7033
Hand/ﬁnger 204 (22.8) 121 (25) 79 (20) p = 0.1235
Elbow 90 (10.1) 52 (11) 36 (9) p = 0.4991
Shoulder/arm 192 (21.5) 114 (24) 75 (19) p = 0.1374
Back 342 (38.3) 195 (40) 139 (36) p = 0.1836
Hip/thigh 231 (25.8) 132 (27) 95 (25) p = 0.3931
Knee/ lower leg 258 (28.9) 143 (30) 113 (29) p = 0.9404
Ankle/foot 148 (16.6) 84 (17) 61 (16) p = 0.5831
Abdomen 532 (59.5) 293 (61) 224 (58) p = 0.4062
Not speciﬁed 312 (34.9) 166 (34) 141 (29) p = 0.5683
doi:10.1371/journal.pone.0156666.t006
Table 7. Treatment of pain.
Total IBD Crohn’s Disease Ulcerative colitis
Treatment of pain N(%) N(%) N(%) p-value
Acetaminophen 333 (37) 189 (39) 131 (34) p = 0.1199
NSAID 112 (13) 63 (13) 45 (12) p = 0.5370
Opioid/Metamizole 142 (16) 83 (17) 50 (13) p = 0.0884
COX-2 inhibitor 22 (3) 16 (3) 6 (2) p = 0.1283
Other 156 (17)
Not speciﬁed 239 (27) 114 (24) 119 (31)
doi:10.1371/journal.pone.0156666.t007
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Impact of pain on quality of life
When assessing the impact on quality of life 528 patients (59%) of the patients had an impact
on the duties of daily life, with a median of 3/10 (0: no impact, 10: very strong impact), 329
(37%) had no impact and 37 (4%) did not specify. 513 patients (57%) had an impact on their
work with a median of 4/10 (0: no impact, 10: very strong impact), 344 (39%) had no impact
on work, 37 (4%) did not specify. The general quality of life was significantly lower in patients
suffering of pain compared to those without pain (38 vs. 77; (-100 very bad; 100 very good)
p<0.0001).
Discussion
Using data from 1,263 SIDBCS patients we showed prevalence of pain in IBD patients was
high. With 71% of our patients reporting pain, pain is present in many more patients than gen-
erally assumed. This is consistent with data from Germany were a high prevalence of pain
(87.9%) was found in a much smaller cohort of 334 patients[29]. When comparing CD and UC
patients separately we could find no significant difference in the occurrence of pain. This is in
line with the study by Schirbel et al. and also Heikenen et al. who evaluated presenting symp-
toms of IBD in a children cohort[29, 44].
For a significant number of patients with IBD chronic pain is a growing problem and has a
large impact on quality of life. Due to its frequency and possible direct relation to a hypersensi-
tivity state due to the inflammatory process, it has even been proposed to add chronic pain to
the list of extraintestinal manifestations of IBD[39, 45].
Furthermore, we showed that pain is a longstanding problem for the majority of the patients
affected. 52% of patients experiencing pain>5 years with only 2% reporting pain since less
than 1 month. In a subgroup analysis comparing CD and UC, statistically more UC patients
only suffered from pain in the last 1–2 years compared to CD (p = 0.0026). This reflects that
pain in UC may be of shorter duration compared to CD. A possible explanation for this could
be that CD patients, due to its higher prevalence of EIM, suffer more frequently of longer a
duration of pain in comparison to UC [46]. In an evaluation of EIM in the SIBDCS by our
group 43% of CD compared to 31% of UC patients had one to five EIMs[7]. Even though we
could find that the disease duration in the UC patients was shorter than in the CD disease
patients (14 years versus 16 years, p = 0.002), we don’t see this difference as relevant for the
interpretation of the pain duration, especially regarding pain in the last 1–2 years.
The main pain localization was abdominal pain (59.5%), but a large proportion of patients
also suffered from back pains, joint pains and headaches. Back pain was reported in 38.3% and
28.9% of patients suffered of knee pain. Furthermore 22.8% of IBD patients had pain in the
hand and finger joints and 21.5% reported shoulder pain. This is in line with the literature
showing that arthropathies are the most common extraintestinal manifestations in IBD[4, 6–
16]. Of note the recognition of EIM is of great importance, since we could show that in one
quarter of patients with IBD, EIMs appeared before the time of IBD diagnosis[47]. In a study
by van der Have et al. IBD patients with back/joint pain reported a significantly lower quality
of life and work productivity compared with IBD patients without back/joint pain[48]. In our
cohort pain also had a strong impact on the health related quality of life (HRQOL). 59% of
patients reported an impact on the HRQOL. Furthermore, HRQOL was significantly lower in
patients suffering of pain as compared to those without pain (38 vs. 77; (-100 very bad; 100
very good) p<0.05.
When characterizing pain, the majority of patients reported pain attacks with no pain in
between (55%). On the other hand, a substantial part of patients (40%) reported not being pain
free between the pain attacks or even having a constant pain.
Pain in IBD
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Notably, we show that pain is undertreated: one fourth of the patients reporting pain did
not receive pain treatment. Given the high prevalence of joint and back pain and the know effi-
cacy of physiotherapy it is surprising that only 13% of the patients received physiotherapy[49].
When accessing the different kinds of pain treatment, the majority received acetaminophen.
However, a substantial part of patients was treated with NSAIDS despite that there is substan-
tial evidence that there is a risk of exacerbation of IBD after treatment with NSAIDs. In a study
by Takeuchi et al. nonselective NSAIDs were associated with a 17%-28% relapse rate within 9
days of ingestion[32–34].
Our study has strengths, but also limitations. A clear strength is the large cohort that we
studied with 1263 completed questionnaires, making it, to our best knowledge, the largest
study on this topic in IBD up to date.
The limitations of our study however, include that, due to the study design and the fact that
we did not control unreturned questionnaires we can face a reporting bias. Patients who actu-
ally suffer from pain due to IBD might want to share their feelings, while patients that do not
suffer would be more enticed to completely discard the questionnaire. This would result in
overestimation of pain prevalence in our study. Against this limitation speaks, that compared
to the German study by Schirbel et al. with 387 IBD patients, which had a response rate of
96.8%, our prevalence of pain was not higher[29].
In summary, using a nationwide patient cohort of IBD patients we have demonstrated that
prevalence of pain in IBD patients is high and that it is present in many more patients than
generally assumed. Further more pain has a substantial impact on the HRQOL. Thus, an
increased awareness is mandatory to address this frequent complication in the course of IBD.
Furthermore, it underlines the importance of pain management in IBD.
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